Abbotts – COOPER GENERAL NEWS

Elon Musk declined to take Texas abortion law directly into account on Thursday after Governor Greg Abbott said the CEO of Tesla and SpaceX endorsed his state’s “social policy” after implementing the severely restrictive measure.

“In general, I believe the government should seldom impose its will on people while trying to maximize their cumulative happiness,” Musk told CNBC in a tweet.

“But I’d rather stay out of politics,” said Musk, whose companies and private foundations are expanding their businesses in Texas.

Abortion rights advocates and vendors say the law sets the precedent for abortion protection set in 1973 under Roe v. Wade was set to effectively cancel. President Joe Biden and others in his administration, as well as House Speaker Nancy Pelosi, D-California, have vowed to do so after the Supreme Court refused to block the law from going into effect.

Earlier Thursday, Abbott told CNBC’s “Squawk on the Street” that the new law and other politically divisive laws on social issues will not make his state any less attractive to businesses or individuals.

“You need to understand that there are a lot of companies and a lot of Americans who like the social positions of the state of Texas,” Abbott said.

“This is not slowing down the companies coming into the state of Texas at all. In fact, it is speeding up the process of companies coming into Texas,” Abbott said.

He added that Musk “had to get out of California because of California’s welfare policy, and Elon keeps telling me that he likes Texas welfare policy.”

Musk personally moved to Texas from California last year, which could save him billions of dollars in taxes. He had not shared his thoughts on the Heartbeat Abortion Act, which also empowers private individuals to sue anyone who “aids” and “incites” most abortions.

Musk has shown little reluctance to meddle on political issues in the past.

For example, in early 2020, amid the early waves of the pandemic, Musk slapped government stay-at-home orders, calling them “fascist” in a text over Tesla’s earnings call for the first quarter of 2020.

Under his direction, Tesla then filed a lawsuit against California’s Alameda County and eventually withdrew it, alleging its health ordinances were in conflict with state policy on business closings.

Last year, Musk donated to three Republican anti-abortion lawmakers and four Democratic lawmakers who support abortion law, giving $ 2,800 each, according to money-in-politics tracker OpenSecrets.org.

Both Tesla and SpaceX have sizable operations in Texas. Tesla is currently building its second US auto plant outside of Austin. And SpaceX has been operating in the state since 2003.

Musk said on March 31 that the company will need to hire more than 10,000 people for the new Texas facility by 2022.

Tesla’s headquarters are currently still in Palo Alto, California, and Tesla operates its first U.S. auto assembly plant nearby in Fremont. But last May, Musk threatened to move these headquarters and future development to Texas and Nevada in protest of pandemic-related restrictions in the Golden State.

Abbott Laboratories BinaxNow kit

Abbott Labs

The Food and Drug Administration announced on Wednesday that it has approved Abbott Labs’ rapid Covid-19 test for home use, despite doctors having to prescribe the test for patients.

The test, which is an antigen test that gives results in about 15 minutes, was previously only approved for trained personnel. With the new release, however, patients can test themselves at home with the virtual support of a doctor. It is the third test approved in the US that “can be used entirely at home,” said Dr. Jeff Shuren, director of the FDA Center for Devices and Radiological Health, in a statement.

Abbott has partnered with telemedicine provider eMed to deliver the test, which is called BinaxNOW and costs $ 25 for home use, at home and oversee the collection and testing process. Patients collect the sample themselves with a nasal swab and an app helps control the testing process and deliver results, Abbott said.

Anyone 15 years or older who is suspected of having Covid-19 by their doctor and who is within the first seven days of symptoms appearing can take the test, according to the FDA. The test can also be used on people 4 years and older, although an adult must collect the sample, the agency said.

“The FDA continues to approve COVID-19 tests, which will give more Americans access to more testing flexibility and options,” said FDA Commissioner Dr. Stephen Hahn in a statement. “The BinaxNOW COVID-19 Ag home test will have a significant manufacturing base and have the potential to support testing for millions of people.”

Abbott expects to run 30 million tests at home in the first quarter of 2021 and another 90 million in the second quarter. The FDA noted that antigen tests are not as accurate as many molecular tests.

“As the pandemic has developed, the need for rapid tests has grown. Unfortunately, we still hear that many people cannot access tests as quickly as they need,” said Robert Ford, Abbott President and CEO, in one Explanation. “That’s why Abbott is bringing our BinaxNOW rapid test and our NAVICA platform home.”

The FDA first approved the test for use by trained personnel in August, touting it as the first Covid-19 test, costing about $ 5 and providing results in minutes on a test card without laboratory equipment, similar to a pregnancy test. The US quickly bought 150 million of the tests for $ 750 million to expand testing capacity.

However, it costs $ 25 to use the test at home, more than what it costs in medical facilities, Abbott said Wednesday.

“The FDA’s approval of the BinaxNOW card test for home use means we should be running tens of millions of COVID-19 tests in the coming months that Americans can use without leaving their homes,” said Alex Azar, Minister of Health and human services, in a statement on Wednesday.

Approval comes after the FDA approved Ellume’s home Covid test on Tuesday. This product has been approved for use on individuals aged 2 years and over and does not require a prescription.